HS-IT201 Injection in the Treatment of Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT201) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.